Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind phase III study of QL2109 vs DARZALEX FASPRO in combination with pomalidomide and dexamethasone for relapsed or refractory multiple myeloma
CTR20244775Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of QL2109 in multiple myeloma (MM) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Proportion of patients with ≥VGPR at 24 weeks. Started Feb 2025; status: active.
02
Drugs
QL2109
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20244775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244775.